Following FDA review of this investigational new drug application (IND), the company plans to initiate a Phase I clinical trial of PX-866.
Robert Kirkman, president and CEO of Oncothyreon, said: “This IND for PX-866 demonstrates the continued advancement of Oncothyreon’s small molecule oncology pipeline. In addition to the planned trial of PX-866, Oncothyreon is currently conducting a Phase II trial of PX-12, a small molecule inhibitor of thioredoxin-1, in patients with advanced pancreatic cancer and a Phase I trial of PX-478, a small molecule inhibitor of HIF-1 alpha, in patients with advanced solid tumors or lymphomas.”